stockrowCorcept Therapeutics Incorporated (CORT) vs Madrigal Pharmaceuticals, Inc. (MDGL)
- Corcept Therapeutics Incorporated CORT 72.79 +1.62%
- Madrigal Pharmaceuticals, Inc. MDGL 397.66 −0.61%
Corcept Therapeutics Incorporated and Madrigal Pharmaceuticals, Inc. are both Biotechnology companies. Madrigal Pharmaceuticals, Inc. is the larger, with a market value of $9.3B against $7.8B — 1.2× the size. Madrigal Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 47.5×. Madrigal Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 92.8% against 30.0%. Corcept Therapeutics Incorporated has the higher net margin (16.5% vs −10.9%) and the higher return on invested capital (15.0% vs −1,480.3%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 14 and Madrigal Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | CORT | MDGL | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.54% | 90.96% | 65.16% |
| Operating margin | 11.51% | (10.69%) | 0.00% |
| Net margin | 16.54% | (10.89%) | 0.00% |
| Free cash flow margin | 20.20% | (11.81%) | 0.00% |
| Return on equity | 21.74% | (24.82%) | (50.12%) |
| Return on assets | 17.16% | (11.12%) | (45.60%) |
| Return on invested capital | 14.97% | (1,480.32%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack